5 January 2023
\n \n \n \nWe are delighted to announce that three researchers have been awarded the Associate Professor title, in recognition of their research achievements, contribution to teaching, and contribution to the general work of the Nuffield Department of Medicine.
\n \n\n \n \n16 December 2022
\n \n \n \nMore than 40,000 doses of Oxford\u2019s Ebola vaccine have been manufactured by Serum Institute of India (SII) in just 60 days and doses shipped to Uganda.
\n \n\n \n \n8 December 2022
\n \n \n \nThe inaugural MRC Impact Prize recognises teams who have made outstanding impacts in health and medical research. The winners will be announced at a ceremony in the spring.
\n \n\n \n \n5 December 2022
\n \n \n \nContinual monitoring of genetic changes in parasite populations is a powerful tool for analysing malaria outbreaks and identifying emerging multidrug-resistant malaria strains, say researchers from NDM\u2019s Mahidol-Oxford Tropical Medicine Research Unit (MORU).
\n \n\n \n \n2 December 2022
\n \n \n \nThe study from the Worldwide Antimalarial Resistance Network (WWARN) provides compelling evidence that artemether-lumefantrine should now replace quinine as the treatment of choice in the first trimester.
\n \n\n \n \n25 November 2022
\n \n \n \nThe Leedham Lab at the Wellcome Centre for Human Genetics in the Nuffield Department of Medicine (NDM) has been awarded over \u00a32m from Cancer Research UK to develop a new tool that could help guide how bowel cancer patients are treated in the future.
\n \n\n \n \n17 November 2022
\n \n \n \nA vaccine developed by the Oxford Vaccine Group\u2019s Prof Teresa Lambe and supported in clinical trials and manufacture scale-up by researchers from Nuffield Department of Medicine's Jenner Institute has been recommended for inclusion in a ring vaccination trial to combat a Sudan ebolavirus outbreak in Uganda.
\n \n\n \n \n8 November 2022
\n \n \n \nResearchers from the Nuffield Department of Medicine\u2019s Jenner Institute have today reported the findings from a study investigating whether previously identified correlates of protection associated with the risk of tuberculosis (TB) disease could also be associated with the risk of infection from the bacteria that causes TB.
\n \n\n \n \n4 November 2022
\n \n \n \nA phase I/IIa clinical trial that the Nuffield Department of Medicine's Jenner Institute collaborated on has demonstrated that a T-cell therapeutic HIV vaccine was associated with better control of the virus rebound when antiretroviral therapy (ART) was temporarily withdrawn.
\n \n\n \n \n25 October 2022
\n \n \n \nEstablished in 1998, the Academy of Medical Sciences is one of the four UK National Academies, coordinating scholarly research activities and standards in the UK.
\n \n\n \n \n19 October 2022
\n \n \n \nHealth and care research in Oxford is to receive \u00a3122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the two NIHR Biomedical Research Centres.
\n \n\n \n \n17 October 2022
\n \n \n \nResearchers from the Nuffield Department of Medicine have today reported new findings from a study exploring how certain genes can help generate a strong immune response following vaccination with two commonly used COVID-19 vaccines \u2013 identifying a particular gene associated with a high antibody response.
\n \n\n \n \n12 October 2022
\n \n \n \nA University of Oxford team has been awarded a grant to study one of the major unsolved questions about asthma \u2013 why women are more likely to have it than men and why they are twice as likely to die from it.
\n \n\n \n \n8 September 2022
\n \n \n \nResearchers from the NDM's Jenner Institute and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of the candidate malaria vaccine, R21/Matrix-M\u2122 \u2013 which previously demonstrated high-level efficacy of 77% over the following 12 months in young west African children in 2021.
\n \n\n \n \n1 September 2022
\n \n \n \nFollowing on from the tragic death of Dr Ling Felce at the Plain roundabout in March 2022, the CAMS-Oxford Institute within the Nuffield Department of Medicine are seeking funds to start an award in her memory.
\n \n\n \n \n23 August 2022
\n \n \n \nThe team behind the world-leading RECOVERY trial of COVID-19 treatments are leading a new study investigating a potential treatment for people who have been diagnosed with monkeypox. The National Institute for Health and Care Research (NIHR) has commissioned and funded the study and the first patients have now been recruited.
\n \n\n \n \n18 August 2022
\n \n \n \nWe are delighted to announce that six researchers have been awarded the title of Professor, in recognition of their research achievements, contribution to teaching, and contribution to the general work of the Nuffield Department of Medicine.
\n \n\n \n \n4 August 2022
\n \n \n \nThe inflammatory diseases company\u2019s rapid ascent and exit underscores the importance of friendships, partnerships and networks in innovation.
\n \n\n \n \n27 July 2022
\n \n \n \nResearchers from the University of Oxford have today reported new findings from a Phase 1 clinical trial studying the immune response and safety of their newly-developed single shot rabies vaccine, ChAdOx2 RabG.
\n \n\n \n \n6 July 2022
\n \n \n \nAcademics from NDM's Jenner Institute and Ludwig Institute for Cancer Research have become the latest to join the 1,900 eminent life scientists in Europe and beyond that make up the European Molecular Biology Organization (EMBO).
\n \n\n \n \n